- In April 2025, ResMed, a leading provider of sleep apnea equipment, confirmed that its products are exempt from U.S. tariffs imposed under President Donald Trump's 'Liberation Day' policy. This exemption, upheld by the White House, applies to disability-related equipment, ensuring continued affordability and accessibility for patients relying on home care devices
- In January 2025, Cardinal Health announced significant investments in its at-Home Solutions division, including the addition of three new warehouses dedicated solely to the delivery of home medical supplies. These strategic expansions aim to enhance efficiency and speed in delivering medical supplies to patients, positioning the company to meet the growing demand for home healthcare services
- In November 2024, Medtronic received U.S. Food and Drug Administration (FDA) approval for its new InPen smartphone software and announced the release of its new Smart MDI system. This system provides real-time information about multiple daily injection (MDI) therapy, enhancing diabetes management for patients using insulin therapy
- In September 2024, Abbott Laboratories announced that its over-the-counter continuous glucose monitor, Lingo, is now available in the U.S. The Lingo aims to help users monitor glucose levels, providing insights into glucose spikes and aiding in better diabetes management
- December 2024, Medline, a leading manufacturer and distributor of medical supplies worldwide, confidentially filed for an initial public offering (IPO) in the United States, potentially valuing the company at up to USD 50 billion. The specific size of the offering remains unspecified, though it is estimated to raise around USD billion
